Neuroendocrine tumors future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Neuroendocrine tumors}} {{CMG}} == Overview == ==Future or Investigational Therapies== Therapies based on growth factor inhibitors are in the experimental stage....") |
(Mahshid) |
||
| (3 intermediate revisions by 3 users not shown) | |||
| Line 2: | Line 2: | ||
{{Neuroendocrine tumors}} | {{Neuroendocrine tumors}} | ||
{{CMG}} | {{CMG}} | ||
== Overview == | == Overview == | ||
| Line 10: | Line 9: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Needs content]] | |||
[[Category:Disease]] | |||
[[Category:Endocrinology]] | |||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Endocrinology]] | |||
[[Category:Surgery]] | |||
Latest revision as of 03:00, 27 November 2017
|
Neuroendocrine tumors Microchapters |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Future or Investigational Therapies
Therapies based on growth factor inhibitors are in the experimental stage. These inhibitors of epidermal growth factor receptors (EGFRs), of vascular endothelial growth factor receptors (VEGFRs), and of angiopoietin-related growth factor (AGF) include imatinib, sunitinib, temozolide, thalidomide, sorafenib, and panitumumab.